Sign in

    Susan Lee

    Senior Equity Research Analyst at Maxim Group

    Susan Lee is a Senior Equity Research Analyst at Maxim Group, specializing in healthcare and biotech sector analysis with a focus on emerging and mid-cap companies. She covers firms such as Sorrento Therapeutics, Onconova Therapeutics, and AVEO Pharmaceuticals, providing data-driven insights and actionable investment recommendations. With more than a decade of industry experience, Susan began her financial career at a boutique investment bank before joining Maxim Group, where she has built a track record of accurate forecasts and successful stock picks resulting in above-industry average returns. She holds FINRA Series 7 and 63 licenses and is recognized for her expertise in identifying clinical-stage investment opportunities and her consistent outperformance versus sector benchmarks.

    Susan Lee's questions to SELLAS Life Sciences Group (SLS) leadership

    Susan Lee's questions to SELLAS Life Sciences Group (SLS) leadership • Q3 2016

    Question

    Susan Lee from Maxim Group, on behalf of Jason McCarthy, asked for an update on the clinical development path for the GALE-301/302 programs and inquired about upcoming catalysts for the ongoing investigator-sponsored NeuVax studies.

    Answer

    President & CEO Mark Schwartz stated that for GALE-301/302, the company is still aggregating data from the Phase I/II trials to determine the optimal path forward. For NeuVax, he highlighted that enrollment for the Phase IIb combination trial with trastuzumab is expected to complete in Q1 2017, with an interim efficacy analysis in Q1 2018. He also noted that discussions with Dr. Reddy's for the gastric cancer trial are continuing. SVP of IR & Corporate Communications Remy Bernarda added that the DCIS trial is anticipated to initiate by the end of the year.

    Ask Fintool Equity Research AI